BenevolentAI

BenevolentAI, a leading clinical-stage company, is revolutionizing the field of drug discovery and development with its innovative use of artificial intelligence (AI). The company’s proprietary Benevolent Platform is an experimental drug discovery platform that leverages AI technologies to find new medicines for several serious diseases, including Parkinson’s disease. BenevolentAI’s approach has proven to be significantly faster than traditional drug discovery methods. In just four years, the company has produced 24 drug candidates.